Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
05/2003
05/08/2003WO2002094836A3 Methods for preparation and use of psorospermin analogs
05/08/2003WO2002085414A3 Nsaid formulations comprising lecithin oils for protecting the gastrointestinal tract and providing enhanced therapeutic activity
05/08/2003WO2002081499A3 Somatostatin agonists
05/08/2003WO2002072608A3 POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCηRECEPTORS
05/08/2003WO2002064129A3 Compositions of biochemical compounds involved in bioenergy metabolism of cells
05/08/2003WO2002053089B1 Stable skin conditioning compositions containing retinoid boosters
05/08/2003WO2002048152A3 Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
05/08/2003WO2002036110A3 Oral self-emulsifying formulations of pyranone protease inhibitors
05/08/2003WO2002026223A3 Catecholamine pharmaceutical compositions and methods
05/08/2003WO2002024715A3 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
05/08/2003WO2002010216A3 Proteins and nucleic acids encoding same
05/08/2003US20030088312 Use of cladribine on a stent to prevent restenosis
05/08/2003US20030088103 PPARgamma modulators
05/08/2003US20030088101 E-ring expanded camptothecin derivatives
05/08/2003US20030088097 E.g., tert-butyloxycarbonyl-protected 2-(2,2,2-trifluoroethyl)hexahydroimidazo(1,5-a)pyrazine
05/08/2003US20030088085 MPROT12 polynucleotides and methods thereof
05/08/2003US20030088061 Materials and methods to modulate ligand binding/enzymatic activity of alpha/beta proteins containing an allosteric regulatory site
05/08/2003US20030087964 Method and pharmaceutical composition for the treatment of cancer
05/08/2003US20030087963 Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
05/08/2003US20030087956 Useful in the treatment of disease mediated by the interaction between VCAM-1 and/or fibronectin and the integrin receptor alpha 4 beta 1.
05/08/2003US20030087950 New alpha-amino acid sulphonyl compounds
05/08/2003US20030087949 For treating neurodegenerative diseases, diseases of circulatory organs, hepatitis, renal diseases, inflammatory skin disorders, radiation disorders, viral diseases, prion diseases, etc.; preservatives
05/08/2003US20030087947 Novel photosensitizers of 9-hydroxypheophorbide-a derivatives used for photodynamic therapy
05/08/2003US20030087945 Sulfonylaminocarboxylic acids
05/08/2003US20030087924 Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
05/08/2003US20030087923 4-Amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases
05/08/2003US20030087922 Aryl substituted 2-aminopyrimidines and 2-aminopyridines
05/08/2003US20030087921 Especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa.
05/08/2003US20030087919 Rho-kinase inhibitors
05/08/2003US20030087916 Pyrimidin-4-one compounds
05/08/2003US20030087910 E.g., O-(2-quinolinylmethyl)-N-quinaldoyl-D,L-tyrosine
05/08/2003US20030087903 Mevinolin derivatives
05/08/2003US20030087902 Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents
05/08/2003US20030087901 Compounds and methods for modulation of estrogen receptors
05/08/2003US20030087899 Administering a stress-activated protein kinase inhibitor, particularly a fused pyrrolocarbazole compound.
05/08/2003US20030087898 Opioid receptor antagonists; treating irritable bowel syndrome, drug addiction or dependency, depression, and eating disorders.
05/08/2003US20030087897 Containing carboxylic acid groups; diagnosis; prophylaxis
05/08/2003US20030087895 Fused imidazole derivatives as multidrug resistance modulators
05/08/2003US20030087892 Condensed azepines as vasopressin agonists
05/08/2003US20030087883 Therapeutic 5-HT ligand compounds
05/08/2003US20030087880 Hydroxy-benzoic acid derivatives; bactericides
05/08/2003US20030087878 Methods and formulations for minimizing spasticity in blood vessel grafts
05/08/2003US20030087868 Administration of a vector to cells in vivo comprising and expressing a transgene encoding beta-glucosidase, the vector is taken up by the cells, the transgene is expressed therein and and beta-glucosidase is produced
05/08/2003US20030087861 Administering mixture of antibody and drug; cancer sensitivity
05/08/2003US20030087842 Indolocarbazole anticancer agents and methods of using them
05/08/2003US20030087839 Combined preparations comprising morpholine anthracyclines and anticancer agent
05/08/2003US20030087832 Anticancer agents; antidiabetic agents, anticholesterol agents, cardiovascular disorders, osteoporosis
05/08/2003US20030087831 1,3,4-Oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient
05/08/2003US20030087830 Low molecular weight components of cartilage, complexes of metals with amino acids, DI-peptides and analogs thereof; processes for preparation and therapeutic uses thereof
05/08/2003US20030087828 Peptide derivatives and pharmaceutically acceptable salts, thereof, processes for preparation of both, and use thereof
05/08/2003US20030087806 Freeze dried complex; therapy for amyotrophic lateral sclerosis, antidiabetic agents
05/08/2003US20030087801 Methods for treatment using novel ligands of the neuropeptide receptor hfgan72
05/08/2003US20030087433 Activator protein for use in cell propagation and cosmetics
05/08/2003US20030087412 Nucleotide sequences coding polypeptide for use in the prevention and treatment of tumors, nervous system, cardiomyopathy, viral and metabolic diseases
05/08/2003US20030087378 Nucleotide sequences coding polypeptide for use in the diagnosis, prevention and treatment of cancer, psoriasis and nervous system disorders
05/08/2003US20030087377 Nucleotide sequences coding polypeptide for use in the diagnosis, prevention and treatment of cancer, psoriasis and nervous system disorders
05/08/2003US20030087343 Novel SLGP nucleic acid molecules and uses therefor
05/08/2003US20030087339 Alzheimer's disease; Parkinson's disease; rheumatic disorders
05/08/2003US20030087328 Optical probe for use in detecting and measuring translational adjustments to proteins
05/08/2003US20030087307 Compound for use in the prevention and treatment of respiratory and nervous system disorders
05/08/2003US20030087306 Methods for identifying novel multimeric agents that modulate receptors
05/08/2003US20030087299 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
05/08/2003US20030087266 IGs as modifiers of the p53 pathway and methods of use
05/08/2003US20030087255 Peptides which stimulate the immune response and tissue regeneration
05/08/2003US20030086989 Morinda citrifolia enhanced lip treatment
05/08/2003US20030086980 Method for the suppression of visceral pain by regulating T type calcium channel
05/08/2003US20030086977 Forming a free- standing powder comprising at least one antimicrobial metal with atomic disorder; and injecting the free-standing powder in therapeutically effective amounts to the tissue which is to be treated
05/08/2003US20030086976 Pharmaceutical compositions for poorly soluble drugs
05/08/2003US20030086965 Combination chemotherapy
05/08/2003US20030086941 For diagnosing and therapy of gastrin-dependent tumor
05/08/2003US20030086921 For therapy and prophylaxis of allergic conditions, autoimmune diseases and inflammatory diseases
05/08/2003US20030086920 Administering derivative of angiotensin I for the onset of the renal related disorder to be prevented, inhibited or delayed or the symptoms of the renal-related disorder to be ameliorated
05/08/2003US20030086919 Targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor
05/08/2003US20030086914 Method and device for inducing biological processes by micro-organs
05/08/2003US20030086900 Method of treatment using ligand-immunogen conjugates
05/08/2003US20030086898 Method for treating hypercholesterolemia with polyallylamine polymers
05/08/2003CA2466824A1 Pde9 inhibitors for treating cardiovascular disorders
05/08/2003CA2466424A1 Utilization of inhibitors of rho-kinases for stimulating nerve growth, inhibiting scar tissue formation and/or reducing a secondary lesion
05/08/2003CA2466306A1 Di-, tri,- and tetra-peptides having antiangiogenic activity
05/08/2003CA2466032A1 Methods and dosage forms for improving the bioavailability of therapeutic agents
05/08/2003CA2465682A1 Methods of treating leukemia
05/08/2003CA2465632A1 Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
05/08/2003CA2465399A1 Alkane diol derivatives as therapeutic agents for the treatment of bone conditions
05/08/2003CA2465382A1 Indole compound and medicinal use thereof
05/08/2003CA2465369A1 Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
05/08/2003CA2465350A1 Therapeutic quinoline compounds with 5-ht-antagonistic properties
05/08/2003CA2465344A1 Therapeutic quinolone compounds with 5-ht-antagonistic properties
05/08/2003CA2465316A1 Hydroxy substituted amides for the treatment of alzheimer's disease
05/08/2003CA2465140A1 Method for the treatment of overactive bladder
05/08/2003CA2465129A1 Acyclic linker-containing oligonucleotides and uses thereof
05/08/2003CA2465061A1 Substituted (1h)-quinoxalin-2-one compounds and substituted 4-aryl- and 4-heteroarylcyclohexane compounds
05/08/2003CA2465040A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
05/08/2003CA2464995A1 Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
05/08/2003CA2464944A1 An efficient synthesis of 5-heteroatom-containing-pyrazoles
05/08/2003CA2464934A1 Pyrimido [4,5-b] indole derivatives
05/08/2003CA2464889A1 Cytokine-inducing material and cytokine-inducing instrument
05/08/2003CA2464888A1 Pyridine derivatives as nmda-receptor subtype blockers
05/08/2003CA2464727A1 Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
05/08/2003CA2464479A1 Methods and formulations for minimizing spasticity in blood vessel grafts
05/08/2003CA2464353A1 Linear basic compounds having nk-2 antagonist activity and formulations thereof
1 ... 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 ... 1564